New Zealand markets open in 6 hours 55 minutes

Eli Lilly and Company (LLY)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
325.43+3.89 (+1.21%)
As of 10:05AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close321.55
Open322.18
Bid324.34 x 900
Ask324.74 x 1100
Day's range322.18 - 327.33
52-week range226.05 - 341.70
Volume409,353
Avg. volume2,739,504
Market cap310.951B
Beta (5Y monthly)0.38
PE ratio (TTM)51.90
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.92 (1.22%)
Ex-dividend date12 Aug 2022
1y target estN/A
  • GlobeNewswire

    Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results

    Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted shareEarly trends1 indicate that Q1 2022 revenue is expected to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share* in the range of $3.80 - $4.10Commenced shipment of vasopressin, a generic al

  • GlobeNewswire

    ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022. “2021 was a year of substantial corporate and clinical accomplishments for ALX Oncology. We initiated numerous clinical trials, including two Phase 2 trials in head and neck squamous cell c

  • GlobeNewswire

    Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

    - Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery programs - Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc.